Metabolic reprograming of mononuclear phagocytes in progressive multiple sclerosis

Frontiers in Immunology

Volumn 6, Issue MAR, 2015, Pages

  Tannahill, Gillian Margaret ^a,b   Iraci, Nunzio ^a,b   Gaude, Edoardo ^b,c   Frezza, Christian ^b,c   Pluchino, Stefano ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b University of Cambridge   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

EAE; Immune metabolism; Macrophages; Microglia; Mitochondria; Multiple sclerosis; Warburg effect

Indexed keywords

ACETYL COENZYME A; ACTIVIN A; ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE; CD8 ANTIGEN; CITRIC ACID; FUMARIC ACID DIMETHYL ESTER; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON; GLUCOSE TRANSPORTER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; ITACONIC ACID; LIPOPOLYSACCHARIDE; MONOCARBOXYLATE TRANSPORTER; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; SIRTUIN 3; SIRTUIN 6; SOMATOMEDIN C; SUCCINATE DEHYDROGENASE; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ALZHEIMER DISEASE; BRAIN HYPOXIA; CELL ACTIVATION; CELL FUNCTION; CELL METABOLISM; CYTOTOXICITY; ENCEPHALOMYELITIS; GLYCOLYSIS; HUMAN; MONONUCLEAR PHAGOCYTE; MULTIPLE SCLEROSIS; MYCOBACTERIUM TUBERCULOSIS; MYELINATION; PHASE 3 CLINICAL TRIAL (TOPIC); POLARIZATION; REGULATORY MECHANISM; SALMONELLA ENTERICA; SHORT SURVEY;

EID: 84926609385     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00106     Document Type: Short Survey

References (92)

1. Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci (2008) 9:839-55. doi: 10.1038/nrn2480
2. Compston A, Coles A. Multiple sclerosis. Lancet (2008) 372:1502-17. doi:10.1016/S0140-6736(08)61620-7
3. Sorensen PS. New management algorithms in multiple sclerosis. Curr Opin Neurol (2014) 27:246-59. doi:10.1097/WCO.0000000000000096
4. Gray E, Thomas TL, Betmouni S, Scolding N, Love S. Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. Brain Pathol (2008) 18:86-95. doi:10.1111/j.1750-3639.2007.00110.x
5. Werner K, Bitsch A, Bunkowski S, Hemmerlein B, Bruck W. The relative number of macrophages/microglia expressing macrophage colony-stimulating factor and its receptor decreases in multiple sclerosis lesions. Glia (2002) 40:121-9. doi:10.1002/glia.10120
6. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol (2012) 8:647-56. doi:10.1038/nrneurol.2012.168
7. Davies LC, Jenkins SJ, Allen JE, Taylor PR. Tissue-resident macrophages. Nat Immunol (2013) 14:986-95. doi:10.1038/ni.2705
8. Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, et al. Immunological genome, gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol (2012) 13:1118-28. doi:10.1038/ni.2419
9. Chiu IM, Morimoto ET, Goodarzi H, Liao JT, O'Keeffe S, Phatnani HP, et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep (2013) 4:385-401. doi:10.1016/j.celrep.2013.06.018
10. Butovsky O, Bukshpan S, Kunis G, Jung S, Schwartz M. Microglia can be induced by IFN-gamma or IL-4 to express neural or dendritic-like markers. Mol Cell Neurosci (2007) 35:490-500. doi:10.1016/j.mcn.2007.04.009
11. Yamasaki R, Lu H, Butovsky O, Ohno N, Rietsch AM, Cialic R, et al. Differential roles of microglia and monocytes in the inflamed central nervous system. J Exp Med (2014) 211:1533-49. doi:10.1084/jem.20132477
12. Bertrand JY, Jalil A, Klaine M, Jung S, Cumano A, Godin I. Three pathways to mature macrophages in the early mouse yolk sac. Blood (2005) 106:3004-11. doi:10.1182/blood-2005-02-0461
13. Gomez Perdiguero E, Schulz C, Geissmann F. Development and homeostasis of "resident" myeloid cells: the case of the microglia. Glia (2013) 61:112-20. doi:10.1002/glia.22393
14. Ransohoff RM, Cardona AE. The myeloid cells of the central nervous system parenchyma. Nature (2010) 468:253-62. doi:10.1038/nature09615
15. Arno B, Grassivaro F, Rossi C, Bergamaschi A, Castiglioni V, Furlan R, et al. Neural progenitor cells orchestrate microglia migration and positioning into the developing cortex. Nat Commun (2014) 5:5611. doi:10.1038/ncomms6611
16. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity (2003) 19:71-82. doi:10.1016/S1074-7613(03)00174-2
17. Prinz M, Priller J, Sisodia SS, Ransohoff RM. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci (2011) 14:1227-35. doi:10.1038/nn.2923
18. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW. Cytotoxicity of microglia. Glia (1993) 7:111-8. doi:10.1002/glia.440070117
19. Cash E, Zhang Y, Rott O. Microglia present myelin antigens to T cells after phagocytosis of oligodendrocytes. Cell Immunol (1993) 147:129-38. doi:10.1006/cimm.1993.1053
20. Neumann H, Kotter MR, Franklin RJ. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain (2009) 132:288-95. doi:10.1093/brain/awn109
21. Miron VE, Boyd A, Zhao JW, Yuen TJ, Ruckh JM, Shadrach JL, et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci (2013) 16:1211-8. doi:10.1038/nn.3469
22. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol (2011) 11:750-61. doi:10.1038/nri3088
23. Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M, et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell (2014) 159:1312-26. doi:10.1016/j.cell.2014.11.018
24. Trebst C, Sorensen TL, Kivisakk P, Cathcart MK, Hesselgesser J, Horuk R, et al. CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol (2001) 159:1701-10. doi:10.1016/S0002-9440(10)63017-9
25. Mikita J, Dubourdieu-Cassagno N, Deloire MS, Vekris A, Biran M, Raffard G, et al. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult Scler (2011) 17:2-15. doi:10.1177/1352458510379243
26. Vogel DY, Vereyken EJ, Glim JE, Heijnen PD, Moeton M, van der Valk P, et al. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation (2013) 10:35. doi:10.1186/1742-2094-10-35
27. Herder V, Iskandar CD, Kegler K, Hansmann F, Elmarabet SA, Khan MA, et al. Dynamic changes of microglia/macrophage M1 and M2 polarization in Theiler's murine encephalomyelitis. Brain Pathol (2014). doi:10.1111/bpa.12238
28. Shichita T, Ito M, Yoshimura A. Post-ischemic inflammation regulates neural damage and protection. Front Cell Neurosci (2014) 8:319. doi:10.3389/fncel.2014.00319
29. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol (2000) 47:707-17. doi:10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q
30. Hendriks JJ, Teunissen CE, de Vries HE, Dijkstra CD. Macrophages and neurodegeneration. Brain Res Brain Res Rev (2005) 48:185-95. doi:10.1016/j.brainresrev.2004.12.008
31. Frigo M, Cogo MG, Fusco ML, Gardinetti M, Frigeni B. Glutamate and multiple sclerosis. Curr Med Chem (2012) 19:1295-9. doi:10.2174/092986712799462559
32. Nikic I, Merkler D, Sorbara C, Brinkoetter M, Kreutzfeldt M, Bareyre FM, et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med (2011) 17:495-9. doi:10.1038/nm.2324
33. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol (2009) 8:280-91. doi:10.1016/S1474-4422(09)70043-2
34. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev (2011) 91:461-553. doi:10.1152/physrev.00011.2010
35. Tremblay ME, Stevens B, Sierra A, Wake H, Bessis A, Nimmerjahn A. The role of microglia in the healthy brain. J Neurosci (2011) 31:16064-9. doi:10.1523/JNEUROSCI.4158-11.2011
36. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener (2009) 4:47. doi:10.1186/1750-1326-4-47
37. Yang I, Han SJ, Kaur G, Crane C, Parsa AT. The role of microglia in central nervous system immunity and glioma immunology. J Clin Neurosci (2010) 17:6-10. doi:10.1016/j.jocn.2009.05.006
38. Kawanokuchi J, Mizuno T, Takeuchi H, Kato H, Wang J, Mitsuma N, et al. Production of interferon-gamma by microglia. Mult Scler (2006) 12:558-64. doi:10.1177/1352458506070763
39. Cherry JD, Olschowka JA, O'Banion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation (2014) 11:98. doi:10.1186/1742-2094-11-98
40. Arnett HA, Wang Y, Matsushima GK, Suzuki K, Ting JP. Functional genomic analysis of remyelination reveals importance of inflammation in oligodendrocyte regeneration. J Neurosci (2003) 23:9824-32.
41. Kotter MR, Setzu A, Sim FJ, Van Rooijen N, Franklin RJ. Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia (2001) 35:204-12. doi:10.1002/glia.1085
42. Mason JL, Xuan S, Dragatsis I, Efstratiadis A, Goldman JE. Insulin-like growth factor (IGF) signaling through type 1 IGF receptor plays an important role in remyelination. J Neurosci (2003) 23:7710-8.
43. Olah M, Amor S, Brouwer N, Vinet J, Eggen B, Biber K, et al. Identification of a microglia phenotype supportive of remyelination. Glia (2012) 60:306-21. doi:10.1002/glia.21266
44. Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci (2005) 25:8240-9. doi:10.1523/JNEUROSCI.1808-05.2005
45. Michelucci A, Heurtaux T, Grandbarbe L, Morga E, Heuschling P. Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: effects of oligomeric and fibrillar amyloid-beta. J Neuroimmunol (2009) 210:3-12. doi:10.1016/j.jneuroim.2009.02.003
46. Newsholme P, Curi R, Gordon S, Newsholme EA. Metabolism of glucose, glutamine, long-chain fatty acids and ketone bodies by murine macrophages. Biochem J (1986) 239:121-5.
47. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature (2013) 496:238-42. doi:10.1038/nature11986
48. Krawczyk CM, Holowka T, Sun J, Blagih J, Amiel E, DeBerardinis RJ, et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood (2010) 115:4742-9. doi:10.1182/blood-2009-10-249540
49. Warburg O. On the origin of cancer cells. Science (1956) 123:309-14. doi:10.1126/science.123.3191.309
50. Vats D, Mukundan L, Odegaard JI, Zhang L, Smith KL, Morel CR, et al. Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metab (2006) 4:13-24. doi:10.1016/j.cmet.2006.08.006
51. Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriguez-Enriquez S, Moreno-Sanchez R. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem (2009) 9:1084-101. doi:10.2174/138955709788922610
52. Friese MA, Craner MJ, Etzensperger R, Vergo S, Wemmie JA, Welsh MJ, et al. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med (2007) 13:1483-9. doi:10.1038/nm1668
53. de Ceglia R, Chaabane L, Biffi E, Bergamaschi A, Ferrigno G, Amadio S, et al. Down-sizing of neuronal network activity and density of presynaptic terminals by pathological acidosis are efficiently prevented by diminazene aceturate. Brain Behav Immun (2014) 45:263-76. doi:10.1016/j.bbi.2014.12.003
54. Nijland PG, Michailidou I, Witte ME, Mizee MR, van der Pol SM, van Het Hof B, et al. Cellular distribution of glucose and monocarboxylate transporters in human brain white matter and multiple sclerosis lesions. Glia (2014) 62:1125-41. doi:10.1002/glia.22667
55. Faria Dde P, Copray S, Sijbesma JW, Willemsen AT, Buchpiguel CA, Dierckx RA, et al. PET imaging of focal demyelination and remyelination in a rat model of multiple sclerosis: comparison of [11C]MeDAS, [11C]CIC and [11C]PIB. Eur J Nucl Med Mol Imaging (2014) 41:995-1003. doi:10.1007/s00259-013-2682-6
56. Davies AL, Desai RA, Bloomfield PS, McIntosh PR, Chapple KJ, Linington C, et al. Neurological deficits caused by tissue hypoxia in neuroinflammatory disease. Ann Neurol (2013) 74:815-25. doi:10.1002/ana.24006
57. Goldmann T, Wieghofer P, Muller PF, Wolf Y, Varol D, Yona S, et al. A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat Neurosci (2013) 16:1618-26. doi:10.1038/nn.3531
58. Zielasek J, Reichmann H, Kunzig H, Jung S, Hartung HP, Toyka KV. Inhibition of brain macrophage/microglial respiratory chain enzyme activity in experimental autoimmune encephalomyelitis of the Lewis rat. Neurosci Lett (1995) 184:129-32. doi:10.1016/0304-3940(94)11187-N
59. Sadagopan N, Li W, Roberds SL, Major T, Preston GM, Yu Y, et al. Circulating succinate is elevated in rodent models of hypertension and metabolic disease. Am J Hypertens (2007) 20:1209-15. doi:10.1016/j.amjhyper.2007.05.010
60. Toma I, Kang JJ, Sipos A, Vargas S, Bansal E, Hanner F, et al. Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney. J Clin Invest (2008) 118:2526-34. doi:10.1172/JCI33293
61. Kim S, Hwang J, Xuan J, Jung YH, Cha HS, Kim KH. Global metabolite profiling of synovial fluid for the specific diagnosis of rheumatoid arthritis from other inflammatory arthritis. PLoS One (2014) 9:e97501. doi:10.1371/journal.pone.0097501
62. Chouchani ET, Pell VR, Gaude E, Aksentijevic D, Sundier SY, Robb EL, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature (2014) 515:431-5. doi:10.1038/nature13909
63. He W, Miao FJ, Lin DC, Schwandner RT, Wang Z, Gao J, et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature (2004) 429:188-93. doi:10.1038/nature02488
64. Rubic T, Lametschwandtner G, Jost S, Hinteregger S, Kund J, Carballido-Perrig N, et al. Triggering the succinate receptor GPR91 on dendritic cells enhances immunity. Nat Immunol (2008) 9:1261-9. doi:10.1038/ni.1657
65. Bhuniya D, Umrani D, Dave B, Salunke D, Kukreja G, Gundu J, et al. Discovery of a potent and selective small molecule hGPR91 antagonist. Bioorg Med Chem Lett (2011) 21:3596-602. doi:10.1016/j.bmcl.2011.04.091
66. Strelko CL, Lu W, Dufort FJ, Seyfried TN, Chiles TC, Rabinowitz JD, et al. Itaconic acid is a mammalian metabolite induced during macrophage activation. J Am Chem Soc (2011) 133:16386-9. doi:10.1021/ja2070889
67. Michelucci A, Cordes T, Ghelfi J, Pailot A, Reiling N, Goldmann O, et al. Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production. Proc Natl Acad Sci U S A (2013) 110:7820-5. doi:10.1073/pnas.1218599110
68. Infantino V, Convertini P, Cucci L, Panaro MA, Di Noia MA, Calvello R, et al. The mitochondrial citrate carrier: a new player in inflammation. Biochem J (2011) 438:433-6. doi:10.1042/BJ20111275
69. Infantino V, Iacobazzi V, Palmieri F, Menga A. ATP-citrate lyase is essential for macrophage inflammatory response. Biochem Biophys Res Commun (2013) 440:105-11. doi:10.1016/j.bbrc.2013.09.037
70. Nath N, Khan M, Paintlia MK, Singh I, Hoda MN, Giri S. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J Immunol (2009) 182:8005-14. doi:10.4049/jimmunol.0803563
71. Prasad R, Giri S, Nath N, Singh I, Singh AK. GSNO attenuates EAE disease by S-nitrosylation-mediated modulation of endothelial-monocyte interactions. Glia (2007) 55:65-77. doi:10.1002/glia.20436
72. Nath N, Khan M, Rattan R, Mangalam A, Makkar RS, de Meester C, et al. Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity. Biochem Biophys Res Commun (2009) 386:16-20. doi:10.1016/j.bbrc.2009.05.106
73. Dali-Youcef N, Lagouge M, Froelich S, Koehl C, Schoonjans K, Auwerx J. Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann Med (2007) 39:335-45. doi:10.1080/07853890701408194
74. Lakshminarasimhan M, Steegborn C. Emerging mitochondrial signaling mechanisms in physiology, aging processes, and as drug targets. Exp Gerontol (2011) 46:174-7. doi:10.1016/j.exger.2010.08.024
75. Yu J, Auwerx J. The role of sirtuins in the control of metabolic homeostasis. Ann N Y Acad Sci (2009) 1173(Suppl 1):E10-9. doi:10.1111/j.1749-6632.2009.04952.x
76. Cimen H, Han MJ, Yang Y, Tong Q, Koc H, Koc EC. Regulation of succinate dehydrogenase activity by SIRT3 in mammalian mitochondria. Biochemistry (2010) 49:304-11. doi:10.1021/bi901627u
77. Liu TF, Vachharajani VT, Yoza BK, McCall CE. NAD+-dependent sirtuin 1 and 6 proteins coordinate a switch from glucose to fatty acid oxidation during the acute inflammatory response. J Biol Chem (2012) 287:25758-69. doi:10.1074/jbc.M112.362343
78. Liu TF, Yoza BK, El Gazzar M, Vachharajani VT, McCall CE. NAD+-dependent SIRT1 deacetylase participates in epigenetic reprogramming during endotoxin tolerance. J Biol Chem (2011) 286:9856-64. doi:10.1074/jbc.M110.196790
79. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med (2012) 367:1098-107. doi:10.1056/NEJMoa1114287
80. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med (2012) 367:1087-97. doi:10.1056/NEJMoa1206328
81. Belge K, Bruck J, Ghoreschi K. Advances in treating psoriasis. F1000prime Rep (2014) 6:4. doi:10.12703/P6-4
82. van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med (2013) 368:1658-9. doi:10.1056/NEJMc1215357
83. Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med (2013) 368:1657-8. doi:10.1056/NEJMc1211805
84. Schilling S, Goelz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol (2006) 145:101-7. doi:10.1111/j.1365-2249.2006.03094.x
85. Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol (1998) 139:390-5. doi:10.1046/j.1365-2133.1998.02400.x
86. Asadullah K, Schmid H, Friedrich M, Randow F, Volk HD, Sterry W, et al. Influence of monomethylfumarate on monocytic cytokine formation-explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res (1997) 289:623-30. doi:10.1007/s004030050251
87. Cross SA, Cook DR, Chi AW, Vance PJ, Kolson LL, Wong BJ, et al. Dimethyl fumarate, an immune modulator and inducer of the antioxidant response, suppresses HIV replication and macrophage-mediated neurotoxicity: a novel candidate for HIV neuroprotection. J Immunol (2011) 187:5015-25. doi:10.4049/jimmunol.1101868
88. Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther (2012) 341:274-84. doi:10.1124/jpet.111.190132
89. Albrecht P, Bouchachia I, Goebels N, Henke N, Hofstetter HH, Issberner A, et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation (2012) 9:163. doi:10.1186/1742-2094-9-163
90. Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation (2010) 7:30. doi:10.1186/1742-2094-7-30
91. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain (2011) 134:678-92. doi:10.1093/brain/awq386
92. Zhu K, Mrowietz U. Enhancement of antibacterial superoxide-anion generation in human monocytes by fumaric acid esters. Arch Dermatol Res (2005) 297:170-6. doi:10.1007/s00403-005-0598-0